Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Picked Up by Analysts at HC Wainwright

Equities research analysts at HC Wainwright began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a note issued to investors on Thursday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

A number of other equities analysts also recently weighed in on AMLX. Stifel Nicolaus set a $45.00 target price on shares of Amylyx Pharmaceuticals in a report on Thursday. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. Mizuho raised their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Citigroup upped their price target on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $44.14.

Amylyx Pharmaceuticals Stock Up 6.8%

AMLX opened at $29.50 on Thursday. The firm’s fifty day simple moving average is $30.00 and its two-hundred day simple moving average is $20.41. Amylyx Pharmaceuticals has a 52-week low of $10.83 and a 52-week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). Equities research analysts expect that Amylyx Pharmaceuticals will post -1.48 EPS for the current year.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 10,028 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.40, for a total value of $324,907.20. Following the completion of the transaction, the insider directly owned 278,064 shares of the company’s stock, valued at $9,009,273.60. This trade represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total transaction of $831,000.00. Following the sale, the director owned 782,881 shares of the company’s stock, valued at approximately $21,685,803.70. This represents a 3.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,374 shares of company stock valued at $1,815,257 in the last ninety days. Company insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AMLX. BlackRock Inc. acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $158,534,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amylyx Pharmaceuticals by 10.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock worth $3,114,000 after acquiring an additional 16,318 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $705,000. Elmind Capital LP purchased a new position in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $2,011,520. Finally, Nantahala Capital Management LLC bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $8,740,845. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Key Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals